We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > gefapixant

News List

Merck’s Gefapixant (45 mg Twice Daily) Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic Cough drugs.com
September 24, 2020
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced the results from two pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant...
Higher dose of gefapixant hits endpoints in chronic cough trial pharmatimes
March 19, 2020
MSD has revealed new topline efficacy results from two ongoing pivotal Phase III trials, evaluating gefapixant (MK-7264) in refractory or unexplained chronic cough.
P2X3 agonist shows promise in relieving chronic cough pharmaceutical-technology
March 04, 2020
A Phase IIb study by researchers at the University of Manchester, UK, has demonstrated that P2X3 agonist gefapixant relieves refractory or unexplained chronic cough.